Professor Leung is currently the Chair Professor in Gastrointestinal Medicine and the Li Shu Fan Medical Foundation Professor in Gastroenterology of the University of Hong Kong. He was an elected Member of the Academia Europaea in 2025. Prof Leung is the current Editor-in-Chief of the HELICOBACTER journal (since 2024), the Treasurer of the Asia Pacific Association of Gastroenterology (2023-2025) and the Board of Director of the Asia Pacific Digestive Week Federation (2025-2027). His previous positions include the Associate Dean of Research of the LKS Faculty of Medicine (2018 – 2024), the Chief Director of the Clinical Trials Center of the University of Hong Kong (2020-2025) and the past President of the Hong Kong Society of Gastroenterology (2022-2024).

Professor Leung has a wide research interest in gastroenterology and endoscopy including Helicobacter pylori and gastric carcinogenesis, inflammatory bowel disease, artificial intelligence, and screening colonoscopy. He has published more than 370 original articles in leading medical and gastroenterology journals including the Lancet series, Gastroenterology, Gut, and Nature Communications, with a h-index of 77 in Scopus.

Current Position:
Professor, Department of Gastric Surgery, Fudan University Shanghai Cancer Center.
Professor, Department of Oncology, Shanghai medical College, Fudan University

Medical educations:

Membership of medical society:
Co-Chairperson, IGCA Surgical Video Webinar Working Group.
Chairman, Youth Committee of Chinese Gastric Cancer Association (CGCA).
Member, Gastric Cancer Expert Committee of Chinese Society of Clinical Oncology (CSCO).
Member, Chinese Society of Minimally Invasive Surgery.

Clinical practice:
Every year, about 3,000 gastric cancer surgery at the Department of Gastric Surgery, Fudan University Shanghai Cancer Center. I specialize in the management of gastric cancer and focuses on minimally invasive, robotic assisted surgical approaches to management of these cancers. Usually I perform 15 cases of gastric cancer surgery including 10 minimally invasive gastric cancer surgery per week.

Special fields:
Gastric surgery, Surgical oncology, Laparoscopic surgery, Robotic surgery

Scientific focus:
Multidisciplinary and personalized cancer treatment, Less invasive cancer treatment, Conversion therapy in gastric cancer with peritoneal metastasis, Invasion and metastasis of gastric signet ring cell carcinoma (GSRCC)

Clinical trials:
PI of China-Korea Laparoscopic Gastrointestinal Surgery Study Cooperative Group (CKLASS01) study : A multi-country, multi-center randomized controlled trial comparing the quality of life between laparoscopy-assisted distal gastrectomy and totally laparoscopic distal gastrectomy for gastric cancer.

Dr. Vo Duy Long is currently a surgeon and Deputy Head of the Department of Gastrointestinal Surgery at the University Medical Center, Ho Chi Minh City, Vietnam, and also a lecturer in the Department of General Surgery, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam.

Dr. Long graduated from the School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City in 2001. He received his surgical training at the University of Catania, Italy, where he obtained a Master of Science’s degree in Laparoscopy in 2009, and also a Doctor of Philosophy’s degree in 2017.

Since 2015, he has established a multidisciplinary program for the treatment of esophageal and gastric cancers at the University Medical Center in Ho Chi Minh City. Dr. Long has performed laparoscopic gastrectomy and esophagectomy for cancer since 2008, with an annual volume of approximately 150 laparoscopic gastrectomies and 50 minimally invasive esophagectomies. He has delivered numerous presentations at international meetings, including the International Gastric Cancer Congress (IGCC), the Asia-Pacific Gastric Cancer Congress (APGCC), the Japanese Gastric Cancer Association (JGCA), the Korea International Gastric Cancer Week (KINGCA WEEK), the Endoscopic and Laparoscopic Surgeons of Asia (ELSA), the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), and the Asia-Pacific Endo-Lap Surgery Group (APEL).

His research interests include gastric and esophageal cancer, and obesity, with a particular focus on the application of laparoscopy and innovative treatment in these conditions. He received the prestigious Award of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) in 2012 for his study titled “Comparison of Laparoscopic and Open Gastrectomy With Lymph Node Dissection for Gastric Cancer.” He also serves as a reviewer for several leading medical journals and has published extensively.

Dr. Long was the first President of the Upper Gastrointestinal Surgical Society of ASEAN (USAN) and served as the 9th Congress President of the Asia-Pacific Gastric Cancer Congress (APGCC).

Dr. Park is actively performing gastric cancer and bariatric surgeries with many experiences of minimally invasive surgeries such as laparoscopic, robotic or single port gastrectomies. He has strong interest in minimally invasive function preserving surgery in early gastric cancer. He is current President of KLASS. He is participating in many important clinical studies such as KLASS (PI of KLASS 5: Phase III trial for laparoscopic proximal gastrectomy versus total gastrectomy for upper early gastric cancer), REGATTA, sentinel node, etc. He plays an important role in many Korean or International societies. His translational research interest is gastric cancer angiogenesis.

Simon Law graduated with First Class Honors from the University of Cambridge in England and completed his postgraduate training at the Department of Surgery at The University of Hong Kong. He is currently the Department Chairperson, Cheung Kung-Hai Professor of Gastrointestinal Surgery, Chair Professor, and Chief of Esophageal and Upper Gastrointestinal Surgery at the Department of Surgery, School of Clinical Medicine, The University of Hong Kong. In addition, he serves as Chief of Service in Surgery at Queen Mary Hospital and Gleneagles Hospital in Hong Kong.

Throughout his career, Professor Law has specialized in benign and malignant disorders of the upper gastrointestinal tract, with particular focus on esophageal and gastric cancers, motility disorders, and gastroesophageal reflux disease. He has developed expertise in a range of endoscopic diagnostic and therapeutic techniques for foregut diseases, as well as surgical approaches including minimally invasive and robot-assisted procedures. His work also encompasses multimodal treatments for esophageal and gastric cancers.

Beyond his clinical practice, Professor Law has been actively involved in numerous professional organizations in Hong Kong. He has served as a council member of the College of Surgeons of Hong Kong, Chairman of the General Surgery Board, and Chief Examiner for the Joint Fellowship Examination of the Royal College of Surgeons of Edinburgh and The College of Surgeons of Hong Kong. He is a past president of the Hong Kong Society of Upper Gastrointestinal Surgeons and a member of the Education and Accreditation Committee of the Medical Council of Hong Kong.

Professor Law has also played significant roles in international surgical societies. He has served as a Consultant to the International Society of Digestive Surgery (ISDS), Asia Representative on the Member Services Committee of the Society for Surgeons of the Alimentary Tract (SSAT), and Secretary of the Hong Kong-China Chapter of the American College of Surgeons. He was co-chairman of the Education Committee of the International Society of Diseases of the Esophagus (ISDE) and is a past President of the same society. He is an honorary member of the American Surgical Association (ASA), the European Surgical Association (ESA), and the Australia and Aotearoa New Zealand Gastric and Oesophageal Surgery Association.

An accomplished researcher, Professor Law has authored 354 articles and 45 book chapters. He is Associate Editor of Diseases of the Esophagus, and is / has been a member of the editorial board in 15 other journals, including Annals of Surgery and JAMA Surgery. He was Editor of the Year for World Journal of Surgery in 2015. In recognition of his contributions to the field, he has been invited to speak at national and international conferences on more than 400 occasions.

Hyoung-Il Kim, MD, PhD, is Professor and Chief of the Division of Upper Gastrointestinal Surgery at the Department of Surgery, Yonsei University College of Medicine, and Director of the Gastric Cancer Center at Yonsei Cancer Center, Seoul, Korea. He earned his medical degree (2000) and master’s degree (2007) from Yonsei University, and his PhD (2018) from Seoul National University. After completing surgical residency and fellowship training at Severance Hospital, he pursued a research fellowship in molecular imaging at Princess Margaret Cancer Centre, University Health Network, Toronto (2018–2020).

Professor Kim is internationally recognized as a leading expert in minimally invasive and robotic gastric cancer surgery, particularly in reduced-port and single-port approaches. He has served as principal investigator in landmark clinical trials, including KLASS-13 and REPROG, and is actively pioneering advanced strategies for function-preserving surgery, enhanced recovery, and surgical data science. His research also extends to innovative therapies for advanced gastric cancer, including peritoneal metastasis, photodynamic diagnosis and therapy, and artificial intelligence–based outcome prediction.

He has authored more than 200 peer-reviewed publications in high-impact journals, including Jama Surgery, Annals of Surgery, Journal of Gastric Cancer, and Surgical Endoscopy, and has received research support from KHIDI, KGCA, KLASS, and Intuitive Surgical. Professor Kim plays a central role in academic leadership, currently serving as Academic Committee Chair of KINGCA, steering global collaborations through KGCA and IGCA, and leading Korea’s National Integrated Bio-Big Data Construction Project.

Summary
Dr. Kelvin Voon is the Head of Division of Surgery, and a Consultant Upper Gastrointestinal, Bariatric & Robotic Surgeon in Sunway Medical Centre Penang. He completed his specialist training in General and Upper GI Surgery in Malaysia, followed by fellowships in Esophagogastric Cancer Surgery in Shanghai and Clinical Obesity & Bariatric Surgery in Taiwan. He is a fellow of the Royal College of Surgeons of Edinburgh, Ireland and the American College of Surgeons.
Recognized for his contributions in the field of surgery in Malaysia, he was instrumental in establishing the Upper GI & bariatric surgical services in northern region. He previously served as Head of the Department of Surgery at Penang General Hospital, the largest government tertiary hospital in Northern Peninsular Malaysia.
He holds leadership roles in several professional societies including Malaysia Upper GI Surgical Society (MUGIS), Malaysian Society for Metabolic & Bariatric Surgery, as well as the Malaysia Upper GI Fellowship Training Committee. His clinical interests include minimally invasive esophagogastrectomy, robotic surgery, bariatric procedures, endoscopy & clinical nutrition.

Current Position

-

Consultant General, Upper GI, Bariatric & Robotic Surgeon, Sunway Medical Center Penang, Malaysia.

-

Visiting Consultant General, Upper GI & Bariatric Surgeon, Penang General Hospital, Malaysia.

Dr. Hwang is the Fortinet Founders School of Medicine Endowed Professor and specializes in early detection and treatment of gastrointestinal malignancies including esophageal cancer, gastric (stomach) cancer and tumors, pancreatic cancer, bile duct cancer and colon cancer. Dr. Hwang received his bachelor's degree from the University of Illinois at Champaign-Urbana in electrical engineering. He then received his M.D. degree from the University of Chicago and his Ph.D. in bioengineering from the University of Washington. Dr. Hwang performs advanced endoscopic surgical procedures (3rd Space Endoscopy) including endoscopic submucosal dissection (ESD), endoscopic full-thickness resection (EFTR) and per-oral endoscopic myotomy (POEM). Dr. Hwang has both a clinical and research interest in improving the early detection of gastric cancer. He is involved in public policy efforts to increase recognition of gastric cancer risk among high-risk populations, and served as the Chairperson of the Asian American Stomach Cancer Disparity Task Force.

Dr. Duc Trong QUACH is an associate professor of Gastroenterology and vice chair of the Department of Internal Medicine, University of Medicine and Pharmacy at Ho Chi Minh City (UMCH). He currently serves as a Vice-President of the Vietnam Association of Gastroenterology (VNAGE) and Secretary General of the Vietnam Federation for Digestive Endoscopy (VFDE). He was a research fellow of the Japanese Society of Gastroenterology in 2005 and then obtained the advanced fellowship of the Asia-Pacific Society for Digestive Endoscopy in 2009. He received the Ph.D. degree in Gastroenterology in 2011 at UMCH. He has published more than 150 reviews and original papers in local and international journals. His interests include GERD, functional gastrointestinal disorders, Helicobacter pylori, screening strategies for early gastrointestinal cancers and advance therapeutics endoscopy. He has received several awards including the Outstanding Presentation Award at the 14th Biannual Scientific Congress of Vietnamese Nation-wide Medical and Pharmaceutical Schools in 2008, the Medal of Creativeness from the Vietnamese Central Youth League in 2008, the Young Clinicians Program Award of the World Congress on Gastroenterology in 2009 and the Outstanding Teacher Award, Faculty of Medicine, UMCH in 2020.

Ernst Kuipers is Professor of Gastroenterology, with extensive experience in the field of gastrointestinal cancer. He currently serves as Vice President (Research) at Nanyang Technology University, Singapore. He earlier served as Minister of Health, Welfare and Sport of the Netherlands as well as CEO of Erasmus MC University Medical Center in The Netherlands. He was a member of the Governing Board of the National University Health System in Singapore, and a member of the Board of Curaçao Medical Center.

Professor Kuipers is a Fellow of the American Gastroenterological Association, Honorary Member of the European Helicobacter & Microbiota Study Group, and an Honorary Fellow of the Hong Kong Society of Gastroenterology. An esteemed scholar, Professor Kuipers is the recipient of many awards, including the Dutch Ministry of Health Pearl Award and the Influencer of the Year Award in Hospital Healthcare.

Professor Ming-Huang Chen is the Director of the Division of Medical Oncology in the Department of Oncology in Taipei Veterans General Hospital and also a professor in National Yang-Ming Chiao-Tung University. Currently, he is the Academic Chair of the Taiwan Oncology Society and the Chairman of the Taiwan Neuroendocrine Tumor Society. He has numerous board certifications i.e. Boards of Oncology, Hematology, Internal Medicine, and Hospice Care. His main research interests include gastrointestinal malignancy, neuroendocrine tumor diagnosis and treatment as well as involvement in clinical trials including initiation of several Investigator-Initiated Trials. He is also either the first or co-author in more than 140 publications.

Medical Oncology, Yonsei Cancer Center
Department of Internal Medicine, Yonsei University College of Medicine
Director of Songdang Institute for Cancer Research, Yonsei Univ. College of Medicine
Chairman, Board of Directors, Korea Cancer Association (KCA), Seoul, Korea
Chair of International Cooperation Committee, National Academy of Medicine of Korea

Professor Rha is a clinical and translational researcher, leading “Gastric Cancer Research team” and “phase I and early phase clinical trial team” of Yonsei Cancer Center. Her research interests include therapeutic strategies and new drug development, genomics-based biomarker development and pharmacogenomics of gastric cancer, renal cell cancer and urothelial carcinoma. She has published over 400 peer-reviewed articles. As a clinical researcher, she has been involved in various global Phase I-III clinical trials including many novel targeted and immune-oncologic agents.

She is currently actively working as executive committee members in many academic societies, including Korean Cancer Association (KCA), Korean Cancer Study Group (KCSG), Korean Genomic Organization (KOGO), Korean Society of Medical Oncology (KSMO) and Korean Association of IRB (KAIRB). She also serves as a chair of scientific committee, IGCA(International Gastric Cancer Association), a key member of ESMO GI education committee and GI preceptorship for ESMO.

Dr. Emile Woo is a Clinical Associate Professor of Surgery at the University of British Columbia. He is the coauthor for the guidelines for surgical treatment of gastric cancer in his Province and is active in the research of managing gastric cancer in Canada. He has been invited to speak at a number of conferences on this topic and is active in the teaching of young surgeons as the previous co-chair on competency based medicine for general surgery. He also the current President of the Medical Staff at Providence Health Care.

Cancer Center of Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China

Chief Surgeon, Professor, FRCS, Doctoral and Postdoctoral Supervisor

Chief Medical Officer and tenured professor at Tsinghua University,Director of the Cancer Center of Beijing Tsinghua Changgung Hospital, Vice president of Nanfang Hospital, Director of Department of General Surgery of Nanfang Hospital, Founder and Chairman of the Chinese Laparoscopic Gastrointestinal Surgery Study group (CLASS group)

Prof. Guoxin Li is an accomplished surgeon and researcher specializing in minimally-invasive surgery for GI cancer. Prof. Li has been a leading figure in the development and promotion of laparoscopic techniques for the treatment of gastric cancer. He has helped establish the safety, efficacy, and long-term outcomes of these minimally invasive procedures. Numerous surgeons, both in China and internationally, was trained by Prof. Li. His mentorship and teachings have contributed to the broader adoption of MIS and the overall improvement of patient care in the field of GI cancer treatment. He is also dedicated in the intelligent precision minimally invasive surgery, development of MIS devices & instruments, and translation of precision medicine in GI cancer. In the field of basic researches, Prof. Li and his team has dig into the molecular mechanism, biomarkers and tumor microenvironment, and subsequently, contributed to the potential of immunotherapy for gastric cancer.

Dr Yong Wei Peng is the associate director (research) and senior consultant from National University Cancer Institute, Singapore at the National University Hospital. Dr Yong obtained his medical degree and postgraduate training in University of Aberdeen, Scotland. After completing an oncology fellowship at the National University Hospital, he was awarded the A*star international clinical pharmacology fellowship at the University of Chicago. Upon his return to Singapore, he was awarded the Clinician Scientist Award to further his research into personalized therapy. In addition, Dr Yong leads the therapeutic arm of the Singapore Gastric Cancer Consortium and chairs the National Health Group Domain Specific Review Board. His clinical and research interests are gastrointestinal cancer and drug development.

• Chao YAN, MD, postdoctoral fellow at Japan Jichi Medical University, Chief Physician
• Deputy Director of the Department of Gastrointestinal Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Director of the ward 5
• Standing Committee member of Gastric Cancer Professional Committee, Chinese Anti-Cancer Association
• Standing Committee member of peritoneal tumor Professional Committee, Chinese Anti-Cancer Association
• Standing Committee member of the Integrated Rehabilitation Committee for Gastric Tumors, Chinese Anti-Cancer Association
• Director of peritoneal tumor Committee, Shanghai Anti-Cancer Association

Prof Jimmy So graduated from Faculty of Medicine at the Chinese University of Hong Kong in 1991. He received his surgical training in National University Hospital, Singapore. He was trained in Upper Gastrointestinal Surgery, Surgical Oncology, Bariatric Surgery, Therapeutic Endoscopy and Minimally Invasive Surgery. He received fellowship training at Massachusetts General Hospital, Harvard Medical School, USA. He was also appointed as visiting consultant surgeon in Esophageal and Gastric Surgery at the Royal Infirmary in Edinburgh, UK. He established a multidisciplinary program for Esophagogastric cancers in NUH in 2005. He also received fellowship training in gastric and esophageal cancer surgery in Japan, Korea and Hong Kong. He established the Centre for Obesity Management and Surgery (COMS). He is pioneer of peroral endoscopic myotomy (POEM), minimally invasive surgery for gastric cancer, intraperitoneal chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC) in Singapore.

He has published more than 300 peer reviewed scientific papers (H Index of 62, Total citations > 14,858 according to Google Scholar in August 2025) and received over S$15 million research grants for his research. He published his research in medical journals such as Lancet, Nature, Cell, Nature Genetics, Gastroenterology, Gut, Cancer Discovery, Cancer Cell, Journal of Clinical Oncology, Annals of Surgery, BJS and JAMA Surgery. He received the Peritoneal Prize by International Society for the Study of Peritoneum and Pleura (ISSPP) in 2020 which recognized the top researcher in the world in the field of peritoneal carcinomatosis. He delivered the Yaya Cohen Memorial Lecture by College of Surgeons, Singapore in 2018. He has delivered over 150 invited lectures internationally. He was invited regularly to speak at International Gastric Cancer Congress, Annual Scientific Meetings of Japanese Gastric Cancer Association and Korean International Gastric Cancer Week. He has also presented his research at American Gastroenterological Association (AGA), American Society of Clinical Oncology (ASCO), American Society of Gastrointestinal Endoscopy (ASGE), Society of American Gastrointestinal Endoscopic Surgeons (SAGES), International Society for Diseases of Esophagus (ISDE) and World Congress of Endoscopic Surgery. He is founding president of the Asia-Pacific Gastro-esophageal Cancer Congress in 2006. Prof So is the Editor for Gastric Cancer, an official journal of International Gastric Cancer Association (IGCA) and he is also member of editorial board of journals including ESMO GI Oncology, BJS Open, Journal of Gastric Cancer, Cancers, Translational Medicine and Annals of Gastroenterological Surgery.

Prof. Patrick Tan is Dean and Provost’s Chair in Cancer and Stem Cell Biology at Duke-NUS Medical School, Singapore. He is also Executive Director of PRECISE, overseeing Singapore’s National Precision Medicine (NPM) strategy. He received his B.A. (summa cum laude) from Harvard University and MD PhD degree from Stanford University, where he received the Charles Yanofsky Prize for Most Outstanding Graduate Thesis in Physics, Biology or Chemistry. Other awards include the President’s Scholarship, Loke Cheng Kim Scholarship, Young Scientist Award (A-STAR), Singapore Youth Award, Chen New Investigator Award (Human Genome Organisation), President’s Science Award, and the Japanese Cancer Association International Award. He has received the American Association for Cancer Research (AACR) Team Science Award as Team Leader, and the Genome Valley Excellence Award by the Government of Telangana (India). He is a member of the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP), the Singapore Bioethics Advisory Committee (BAC), a Board Member of the International Gastric Cancer Association, Global Alliance for Genomics and Health (GA4GH), Board of Editors for Science and Cancer Discovery, and an advisory member for Qatar Precision Health Institute.

Florian Lordick is a Full Professor of Medicine at the University of Leipzig. He was appointed as director of the University Cancer Center Leipzig in 2012, which is one of 15 German Oncology Centers of Excellence and receives funding from the German Cancer Aid. He also is head of the 2nd Department of Medicine (oncology, gastroenterology, hepatology, and pulmonology) at the University of Leipzig Medical Center and in 2024, he was appointed visiting professor at the Charles University in Prague, Czech Republic.

Dr. Lordick’s scientific focus is on clinical and translational research in gastrointestinal tract tumours with a focus on esophageal and gastric cancers. He has a great interest in multimodality treatment of GI cancers, in personalized medicine, and in cancer survivorship. His research is funded by the German Cancer Aid, the German Ministry of Education and Research and by the European Commission. Dr. Lordick has authored and co-authored more than 500 peer-reviewed articles. Dr. Lordick served as Director of Education at the European Society for Medical Oncology (ESMO), as president of the International Gastric Cancer Association (IGCA), he is a former member of the executive board of the German Cancer Society and former chair of the EORTC Gastrointestinal Tract Cancer Working groups. Since 2024, he is a member of the executive board of the International Cancer Foundation (ICF). He is the Editor-in-Chief of ESMO Gastrointestinal Oncology (Elsevier), official scientific journal of the European Society for Medical Oncology and of Die Onkologie (Springer-Nature), official journal of the German Cancer Society.

Professor and Director of Medical Oncology dept in Sun Yat-sen University Cancer Center

Dr. Feng Wang is currently a professor, assistant president and director in the Department of Medical Oncology at Sun Yat-Sen University Cancer Center, Guangzhou, China. Awarded The National Science Fund for Distinguished Young Scholars. She holds many academic posts, including the National high-level talents, Vice Chairman of Youth Council of China Anti-Cancer Association. She has extensive experience and expertise in the field of Precision treatment and immunotherapy for digestive tract tumors. Dr Wang sees more than thousands of patients with gastrointestinal cancers annually and has initiated or participated in many investigators initiated and NMPA approved clinical trials. Dr. Wang has published over 65 articles, Act as corresponding/co-corresponding or first author, such as Nature Medicine, Cancer Cell, Journal of Clinical Oncology, JAMA Oncology, Annals of Oncology, The Lancet Gastroenterology and Hepatology etc. 10 studies have been written into 9 authoritative guides at home and abroad, such as NCCN, ASCO, CSCO, CACA, etc. She was awarded 5 national invention patents and many prizes including the Second Prize of National Science and Technology Progress Award, First prize of Science and Technology Progress Award of Ministry of Education, First Prize of Chinese Medical Science and Technology Award, “Important Medical Progress 2022” Award of Chinese Academy of Medical Sciences, The 6th “XPLORER PRIZE”etc. She has won many honorary titles such as “National Famous Doctor”, “People‘s Good Doctor” and “Young Scientist of China Anti-Cancer Association”, and has been invited to invited to make oral presentations at major international conferences such as American ASCO, AACR Annual Meeting, European ESMO Annual Meeting, and China CSCO Annual Meeting

Associate Professor Radka Lordick Obermannová, PhD, is a medical oncology consultant at the Department of Comprehensive Cancer Care at the Masaryk Memorial Cancer Institute in Brno. She specializes in treating patients with digestive tract tumors. Her scientific focus on gastrointestinal cancer sparked her research career, especially her interest in optimizing multimodal treatment for esophageal cancer, including predictors of treatment response. Dr. Lordick Obermannová has led the Phase I unit since 2012. She participates in drug development as a principal investigator and co-investigator of Phase I-III clinical trials. She authored national guidelines for treating esophageal and gastric cancers, as well as the ESMO guideline for esophageal cancer. She is an active member of the ESMO faculty group on gastrointestinal non-colorectal cancer and co-leader of the EORTC gastric cancer working group. Additionally, she is a member of the International Gastric Cancer Association (IGCA) and the Czech Cancer Society.

Do-Youn Oh is currently Professor in Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine. She graduated from Seoul National University College of Medicine in 1997, and had residency training in Internal Medicine, and fellowship of Hematology/Medical Oncology training in Seoul National University Hospital. She got her Ph.D Degree in the Department of Internal Medicine, Seoul National University College of Medicine in 2005. Since 2006, she has been working as a professor in Seoul National University Hospital.

Her main research interest is gastric cancer, pancreatic cancer and biliary tract cancer with particular interest in the translational research and early drug development. She has published over 450 peer-reviewed journal articles. She has lots of committee memberships in the medical society, including Korean Cancer Association, Korean Society of Medical Oncology, Korean Cancer Study Group, American Society of Clinical Oncology, American Association for Cancer Research, and European Society of Medical Oncology.

Curriculum Vitae

Education

Professional Experience

Florian Lordick is a Full Professor of Medicine at the University of Leipzig. He was appointed as director of the University Cancer Center Leipzig in 2012, which is one of 15 German Oncology Centers of Excellence and receives funding from the German Cancer Aid. He also is head of the 2nd Department of Medicine (oncology, gastroenterology, hepatology, and pulmonology) at the University of Leipzig Medical Center and in 2024, he was appointed visiting professor at the Charles University in Prague, Czech Republic.

Dr. Lordick’s scientific focus is on clinical and translational research in gastrointestinal tract tumours with a focus on esophageal and gastric cancers. He has a great interest in multimodality treatment of GI cancers, in personalized medicine, and in cancer survivorship. His research is funded by the German Cancer Aid, the German Ministry of Education and Research and by the European Commission. Dr. Lordick has authored and co-authored more than 500 peer-reviewed articles. Dr. Lordick served as Director of Education at the European Society for Medical Oncology (ESMO), as president of the International Gastric Cancer Association (IGCA), he is a former member of the executive board of the German Cancer Society and former chair of the EORTC Gastrointestinal Tract Cancer Working groups. Since 2024, he is a member of the executive board of the International Cancer Foundation (ICF). He is the Editor-in-Chief of ESMO Gastrointestinal Oncology (Elsevier), official scientific journal of the European Society for Medical Oncology and of Die Onkologie (Springer-Nature), official journal of the German Cancer Society.

Current Position
Assistant professor, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine

Education
B.S. Chung-Ang University College of Medicine, Seoul, Korea, 2005-2011
M.S. University of Ulsan College of Medicine, Seoul, Korea, 2014-2016
Ph.D. Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea, 2016-2020

Biography
Dr. Hyung-Don Kim is a medical oncologist and Assistant Professor at Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. His clinical practice and research focus on gastrointestinal cancers, particularly gastric cancer, hepatocellular carcinoma, and GIST. Dr. Kim has been actively involved in clinical and translational research, with a strong interest in identifying predictive biomarkers and mechanism of resistance to immunotherapy in gastric cancer. He has published on the prognostic roles of PD-L1 CPS, mismatch repair status, TMB, and CLDN18.2 in the context of immune checkpoint inhibitor-based therapies. He also conducts cutting-edge translational research focusing on immunogenomic profiling and tumor-immune interactions. He has authored over 100 peer-reviewed publications, including more than 60 as first or corresponding author. As a major author, his work has been published in prestigious journals such as Nature Medicine, Gastroenterology, Journal of Hepatology, Hepatology, and Journal for ImmunoTherapy of Cancer.

Medical Oncology, Yonsei Cancer Center
Department of Internal Medicine, Yonsei University College of Medicine
Director of Songdang Institute for Cancer Research, Yonsei Univ. College of Medicine
Chairman, Board of Directors, Korea Cancer Association (KCA), Seoul, Korea
Chair of International Cooperation Committee, National Academy of Medicine of Korea

Professor Rha is a clinical and translational researcher, leading “Gastric Cancer Research team” and “phase I and early phase clinical trial team” of Yonsei Cancer Center. Her research interests include therapeutic strategies and new drug development, genomics-based biomarker development and pharmacogenomics of gastric cancer, renal cell cancer and urothelial carcinoma. She has published over 400 peer-reviewed articles. As a clinical researcher, she has been involved in various global Phase I-III clinical trials including many novel targeted and immune-oncologic agents.

She is currently actively working as executive committee members in many academic societies, including Korean Cancer Association (KCA), Korean Cancer Study Group (KCSG), Korean Genomic Organization (KOGO), Korean Society of Medical Oncology (KSMO) and Korean Association of IRB (KAIRB). She also serves as a chair of scientific committee, IGCA(International Gastric Cancer Association), a key member of ESMO GI education committee and GI preceptorship for ESMO.